Combination of peucedanum japonicum and bifidobacterium animalis for improving intestinal environment

Abstract

To provide a combination of Peucedanum japonicum and Bifidobacterium animalis for improving the intestinal environment.SOLUTION: A combination of Peucedanum japonicum and Bifidobacterium animalis for improving the intestinal environment.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a combination of Chou Meisou and Bifidobacterium animalis for improving the intestinal environment. [Background technology]

[0002] Approximately 40 trillion intestinal bacteria of approximately 1,000 species live in the human intestine (Non-Patent Document 1), constituting the intestinal microbiota. In recent years, it has been revealed that the balance of the intestinal microbiota has a significant impact on human health. Intestinal bacteria are involved in the metabolism of various substances derived from food and drugs, as well as endogenous substances, and play important roles in human nutrition, physiological functions, infection immunity, carcinogenesis, aging, medicinal efficacy, and other aspects. Intestinal bacteria can be broadly divided into beneficial bacteria, also known as probiotics, such as bifidobacteria and lactic acid bacteria, which are beneficial in terms of intestinal regulation, anti-allergic effects, infection prevention against pathogenic bacteria and viruses, nutrition, and inhibition of the growth of harmful bacteria; harmful bacteria, such as pathogenic Escherichia coli, which are associated with carcinogenesis, liver disease, arteriosclerosis, hypertension, and infectious diseases; and opportunistic bacteria that do not belong to either of these categories. To improve the intestinal microbiota, it is believed that it is important to establish and proliferate beneficial bacteria in the lower gastrointestinal tract.

[0003] On the other hand, prebiotics are known as food components that are not broken down or absorbed in the upper gastrointestinal tract and that act as a nutrient source for probiotics and exert beneficial effects on the host by selectively promoting the growth and activity of probiotics.

[0004] For example, Patent Document 1 discloses a technology that reduces the proportion of Coriobacteriaceae in the intestinal flora and increases the proportion of Veillonellaceae and Faecalibacterium butyricum using a composition containing polydextrose or water-soluble corn fiber.

[0005] Furthermore, for example, Patent Document 2 discloses a technique for growing Lactobacillus casei with high selectivity using highly indigestible galactooligosaccharides.

[0006] As such, various ingredients have been found that are expected to improve the intestinal environment, but the effects are not always sufficient, and there is still a need to develop ingredients and products that have excellent intestinal environment-improving effects. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] Special Publication No. 2014-532710 [Patent Document 2] Japanese Patent Application Laid-Open No. 2011-036203 [Non-patent literature]

[0008] [Non-Patent Document 1] PLoS Biol.2016 Aug 19;14(8) Summary of the Invention

[0009] The present inventors have found that the combination of Chou-mei-sou and Bifidobacterium animalis significantly increases certain beneficial intestinal bacteria, and the present invention is based on this finding.

[0010] Therefore, the present invention provides a combination of Chou Meisou and Bifidobacterium animalis for improving the intestinal environment.

[0011] According to the present invention, the following inventions are provided. (1) A composition for improving the intestinal environment, comprising Chou-mei-sou, for use in combination with Bifidobacterium animalis. (2) A composition for improving the intestinal environment, comprising Bifidobacterium animalis, for use in combination with Chou-mei-sou. (3) A composition for improving the intestinal environment, comprising Chou-mei-sou and Bifidobacterium animalis. (4) The composition according to any one of (1) to (3), wherein the improvement of the intestinal environment includes an increase in the number of one or more bacteria selected from the group consisting of Bacteroides, Bifidobacterium, and Lactobacillus. (5) The composition according to any one of (1) to (4), wherein the improvement of the intestinal environment includes an increase in the number of bacteria of the genus Lactobacillus. (6) The CA was calculated to be 1 per gram of dry weight of Chomeisou, and the number of Bifidobacterium animalis bacteria was 1.0 × 10 7 The composition according to any one of (1) to (5), which is used so that CB / CA is 5 to 10,000, when the value converted to be 1 per CFU is taken as CB. (7) The composition according to any one of (1) to (6), which is a food composition. (8) Use of a combination of Chou-mei-sou and Bifidobacterium animalis for the manufacture of a drug for improving the intestinal environment. (9) The use according to (8), wherein the improvement of the intestinal environment includes an increase in the number of one or more bacteria selected from the group consisting of Bacteroides, Bifidobacterium, and Lactobacillus. (10) The use according to (8) or (9), wherein the improvement of the intestinal environment includes an increase in the number of bacteria of the genus Lactobacillus. (11) The CA was calculated to be 1 per gram of dry weight of Chomeisou, and the number of Bifidobacterium animalis bacteria was 1.0 × 10 7 The use according to any one of (8) to (10), in which CB / CA is 5 to 10,000, when the value converted to 1 per CFU is taken as CB. (12) The use according to any one of (8) to (11), wherein the Chou-mei-sou or Bifidobacterium animalis is in the form of a food composition. (13) Use of a combination of Chou-mei-sou and Bifidobacterium animalis for improving intestinal environment. (14) The use according to (13), wherein the improvement of the intestinal environment includes an increase in the number of one or more bacteria selected from the group consisting of Bacteroides, Bifidobacterium, and Lactobacillus. (15) The use according to (13) or (14), wherein the improvement of the intestinal environment includes an increase in the number of bacteria of the genus Lactobacillus. (16) The CA was calculated to be 1 per gram of dry weight of Chomeisou, and the number of Bifidobacterium animalis bacteria was 1.0 × 10 7 The use according to any one of (13) to (15), in which CB / CA is 5 to 10,000, when the value converted to 1 per CFU is taken as CB. (17) The use according to any one of (13) to (16), wherein the Chou-mei-sou or Bifidobacterium animalis is in the form of a food composition. (18) A combination of Chou-mei-sou and Bifidobacterium animalis for improving the intestinal environment. (19) The combination according to (18), wherein the improvement of the intestinal environment includes an increase in the number of one or more bacteria selected from the group consisting of Bacteroides, Bifidobacterium, and Lactobacillus. (20) The combination according to (18) or (19), wherein the improvement of the intestinal environment includes an increase in the number of bacteria of the genus Lactobacillus. (21) The CA was calculated to be 1 per gram of dry weight of Chomeisou, and the number of Bifidobacterium animalis bacteria was 1.0 × 10 7 The combination according to any one of (18) to (20) is used so that CB / CA is 5 to 10,000, when the value converted to be 1 per CFU is taken as CB. (22) A method for improving the intestinal environment in a subject, the method comprising administering an effective amount of a combination of Chou-mei-sou and Bifidobacterium animalis. (23) The method according to (22), wherein the improvement of the intestinal environment includes an increase in the number of one or more bacteria selected from the group consisting of Bacteroides, Bifidobacterium, and Lactobacillus. (24) The method according to (22) or (23), wherein the improvement of the intestinal environment includes an increase in the number of bacteria of the genus Lactobacillus. (25) The CA was calculated to be 1 per gram of dry weight of Chomeisou, and the number of Bifidobacterium animalis bacteria was 1.0 × 107 The method according to any one of (22) to (24), wherein the CB is administered so that CB / CA is 5 to 10,000, when the value converted to 1 per CFU is taken as CB. (26) The method according to any one of (22) to (25), wherein the chomeisou or Bifidobacterium animalis is in the form of a food composition.

[0012] According to the present invention, a combination of Chou Meisou and Bifidobacterium animalis is provided for improving the intestinal environment.

[0013] According to one aspect of the present invention, there is provided an intestinal environment improving agent comprising Chou-mei-sou for use in combination with Bifidobacterium animalis or a composition comprising Bifidobacterium animalis. Such an intestinal environment improving agent comprising Chou-mei-sou may be a composition comprising Chou-mei-sou for improving the intestinal environment.

[0014] Another aspect of the present invention provides an intestinal environment-improving agent comprising Bifidobacterium animalis for use in combination with Chou-mei-sou or a composition comprising Chou-mei-sou. Such an intestinal environment-improving agent comprising Bifidobacterium animalis may be a composition comprising Bifidobacterium animalis for improving the intestinal environment.

[0015] Another aspect of the present invention provides an intestinal environment-improving agent comprising Chou-mei-sou and Bifidobacterium animalis. Such an intestinal environment-improving agent comprising Chou-mei-sou and Bifidobacterium animalis may be a composition comprising Chou-mei-sou and Bifidobacterium animalis for improving the intestinal environment.

[0016] Subjects whose intestinal environment is improved in the present invention include, but are not limited to, humans, primates including chimpanzees, pet animals such as dogs and cats, livestock animals such as cows, horses, sheep and goats, and mammals such as rodents such as mice and rats. Preferably, the subject whose intestinal environment is improved in the present invention is humans.

[0017] Improvement in the present invention includes the condition of a subject that is not equivalent to that of a healthy subject returning to or approaching a condition equivalent to that of a healthy subject, and the condition of a subject that is equivalent to that of a healthy subject being maintained or becoming better than that equivalent to that of a healthy subject.

[0018] The amounts of Chomeisou and Bifidobacterium animalis used in the composition of the present invention can be determined appropriately depending on the application. Preferably, the CA is calculated to be 1 per gram of dry weight of Chomeisou, and the number of Bifidobacterium animalis bacteria is calculated to be 1.0 x 10 7 When the value converted to 1 per CFU is taken as CB, CB / CA is 5 to 10,000, more preferably 30 to 500, and even more preferably 50 to 200.

[0019] In the present invention, "choumeisou" refers to Peucedanum japonicum, a plant of the Apiaceae family, genus Peucedanum, also known as Peucedanum japonicum. The part used is not limited, but is preferably the leaves or stems, and more preferably the leaves. The "choumeisou" in the present invention can be used as is or after processing, such as drying, as needed. Furthermore, the "choumeisou" in the present invention can also be a chou-meisou extract produced using the whole or part of the chou-meisou.

[0020] The method for producing the Chou Meisou extract of the present invention is not particularly limited and can be produced according to a method commonly used in the art, for example, by extracting the raw material of the extract. The extraction method is not limited to, but includes, for example, hot water extraction, ultrasonic extraction, filtration, reflux extraction, and solvent (e.g., ethanol) extraction. These methods may be carried out alone or in combination of two or more. Furthermore, to obtain a highly pure extract, the extract may be further extracted one or more times using the same method.

[0021] The type of solvent used to produce the Chou-mei-sou extract of the present invention is not particularly limited, and any solvent known in the art may be used as long as it can produce an extract having the desired effect of the present invention. Examples of such solvents include, but are not limited to, water, alcohols having 1 to 4 carbon atoms, ethyl acetate, acetone, chloroform, etc., and two or more of these may be used in combination.

[0022] When Chomeisou (including dried powder, extract, etc.) is commercially available, it may be used as long as it has the desired effect of the present invention.

[0023] Bifidobacterium animalis exists in two subspecies: Bifidobacterium animalis subspecies animalis and Bifidobacterium animalis subspecies lactis. The Bifidobacterium animalis of the present invention may be either subspecies, but is preferably Bifidobacterium animalis subspecies lactis. For example, BB-12 (registered trademark) deposited at DSMZ under accession number DSM15954 can be preferably used.

[0024] In the present invention, improving the intestinal environment includes the intestinal environment of a subject that is not equivalent to that of a healthy person returning to or approaching that of a healthy person, and the intestinal environment of a subject that is equivalent to that of a healthy person being maintained or becoming better than the intestinal environment of a healthy person.

[0025] The means for improving the intestinal environment in the present invention may be, but is not limited to, an increase in bacteria that are beneficial to the subject. Examples of such beneficial bacteria include, but are not limited to, the genera Bacteroides, Bifidobacterium, and Lactobacillus. The increase in such beneficial bacteria may occur in the lower digestive tract (e.g., in the intestine), or may occur in other parts of the digestive tract.

[0026] According to one embodiment of the present invention, the improvement of the intestinal environment in the present invention includes an increase in the number of bacteria of the genus Bacteroides, and preferably an increase in the number of bacteria of Bacteroides fragilis.

[0027] According to another embodiment of the present invention, the improvement of the intestinal environment in the present invention comprises an increase in the number of bacteria of the genus Bifidobacterium.

[0028] According to another embodiment of the present invention, the improvement of the intestinal environment in the present invention includes an increase in the number of bacteria of the genus Lactobacillus.

[0029] According to another embodiment of the present invention, the improvement of the intestinal environment in the present invention comprises an increase in the number of one or more bacteria selected from the group consisting of Bacteroides, Bifidobacterium, and Lactobacillus, and preferably an increase in the number of Lactobacillus bacteria.

[0030] The composition of the present invention may be, but is not limited to, any of a pharmaceutical composition, a cosmetic composition, and a food composition. The composition of the present invention is preferably a food composition.

[0031] When the composition of the present invention is used as a food composition, known ingredients generally used in food compositions can be further blended in. Examples of such ingredients include, but are not limited to, foods such as sugars, fruits, fruit juices, vegetables, and meats, as well as food additives such as sweeteners, high-intensity sweeteners (aspartame, sucralose, glycyrrhizin, saccharin, stevia, dulcin, trichlorosucrose, thaumatin, and acesulfame potassium), flavors, colorants, acidulants, antioxidants, emulsifiers, preservatives, and stabilizers.

[0032] When the composition of the present invention is made into a food composition, it may be made into a health functional food such as a nutrient functional food, a food for specified health uses, or a food with functional claims, or it may be manufactured into a therapeutic food (i.e., a food that serves the purpose of treatment, or a food prepared based on a menu prepared by a nutritionist or the like in accordance with a doctor's dietary prescription), a dietary therapy food, a nursing care food, etc. [Example]

[0033] The present invention will be described in detail based on the following examples, but the present invention is not limited to these examples. Contents are expressed in mass % unless otherwise specified.

[0034] Evaluation of the intestinal microbiota using feces The intestinal flora of the human subjects was measured by the following method.

[0035] Fresh feces were collected from two healthy 40-year-old female donors. The collected feces were suspended in a volume (mL) of 9 times the amount (g) of the collected feces, a freeze-drying protectant for anaerobic bacteria, PreserWell (MPR), vortexed for 1 minute, and frozen until use. Just before starting the culture, the thawed fecal suspension was centrifuged at 1000 rpm for 1 minute, and the supernatant was collected in a new tube. 50 μL of the collected supernatant was added to 20 mL of GAM medium (see Table 1 below).

[0036] [Table 1]

[0037] The supernatant-supplemented GAM medium was supplemented with either no food component or food components (1.3 × 10 7 CFU of Bifidobacterium animalis (strain BB-12) and 0.041 mg of inulin, and 1.3 × 10 7 CFU of Bifidobacterium animalis (BB-12 strain) and 10.67 mg of Chou-meisou (choumeisou) were added to prepare samples for Comparative Examples 1 and 2 and Example 1 (Comparative Example 1 corresponds to the control group (no addition), Comparative Example 2 corresponds to the BB-12 + inulin addition group, and Example 1 corresponds to the BB-12 + Chou-meisou addition group; n = 3 for each donor). Each sample was filled with a gas mixture of N2 (78%), CO2 (20%), and H2 (2%) and then cultured at 37°C for 30 hours with shaking. The culture medium was analyzed for the composition of the major bacterial flora. Data were expressed as the number of bacteria per mL of culture medium (Log10 cells / mL) and expressed as mean ± standard deviation (n = 3). Statistical analysis was performed using Dunnett's test. P < 0.05 (vs. control group) was considered significant. The results are shown in Tables 2 and 3.

[0038] [Table 2]

[0039] [Table 3]

[0040] From the above, it was shown that when BB12 and Chou-mei-sou were combined, beneficial bacterial groups such as Bifidobacterium and Lactobacillus were effectively increased.

Claims

1. A composition for improving the intestinal environment, comprising Chou-mei-sou, for use in combination with Bifidobacterium animalis.

2. A composition for improving the intestinal environment, comprising Bifidobacterium animalis, for use in combination with Chou-mei-sou.

3. A composition for improving the intestinal environment, comprising Chou-mei-sou and Bifidobacterium animalis.

4. The composition according to any one of claims 1 to 3, wherein the improvement of the intestinal environment comprises an increase in the number of one or more bacteria selected from the group consisting of Bacteroides, Bifidobacterium, and Lactobacillus.

5. The composition according to any one of claims 1 to 3, wherein the improvement of the intestinal environment comprises an increase in the number of bacteria of the genus Lactobacillus.

6. The value converted to 1 per 1 g of dry weight of Chou-mei-sou is CA, and the number of Bifidobacterium animalis bacteria is 1.0 x 10 ７ The composition according to any one of claims 1 to 3, for use so that CB / CA is 5 to 10,000, when CB is a value converted to 1 per CFU.

7. The composition according to any one of claims 1 to 3, which is a food composition.

Images